Potential FDA Approval for Novavax Vaccine Sends Stock Even Higher

Yesterday, the U.S. agreed to buy 3.2 million doses of the vaccine

Digital Content Manager
Jul 13, 2022 at 8:59 AM
facebook twitter linkedin

The shares of Novavax, Inc. (NASDAQ:NVAX) are up 2.2% at $71.30 this morning, after Politico reported that the pharmaceutical company's two-dose Covid-19 vaccine could receive approval from the U.S. Food and Drug Administration (FDA) as soon as today. The stock was on the rise yesterday as well, adding 3.9% after the U.S. government ordered 3.2 million doses of the jab ahead of the FDA's pending approval. 

The stock has a ways to go, however, if it wants to work off its 51.2% year-to-date deficit. NVAX's most recent rally was cut short at the 140-day moving average. On the bright side though, the 100-day moving average sits below as potential support. Plus, month-over-month, the equity has added more than 71%. 

Despite this, short sellers have been piling on, rising almost 30% in the last reporting period. The 15.73 million shares sold short now make up 20.3% of the stock's available float, and would take almost three days to cover, at NVAX's average daily pace of trading. 

Options traders, on the other hand, have been much more bullish than usual. This is per Novavax stock's 10-day call/put volume ratio of 3.01 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which sits higher than 92% of readings from the past year. In other words, calls have been getting picked up at a much quicker-thank-usual clip of late. 


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report


Special Offers from Schaeffer's Trading Partners